NorthX Biologics is proud to have the opportunity to support and be a part of AdBIOPRO. “It is a great infrastructure for ground breaking research and development aimed at finding solutions to some of the manufacturing challenges that need a resolution in order to bring advanced therapies to the patients at an affordable cost,” says Ola Tuvesson CTO at NorthX Biologics and member of the AdBIOPRO Centre Board.
We are proud to inform you that NorthX Biologics improved its score from bronze to silver in the International Sustainability Survey (EcoVadis) for the year 2022. We have also implemented more routines and policies at our company to continuously improve the way we operate.
EcoVadis provides holistic sustainability rating services of companies. The rating covers a broad range of non-financial management systems including environmental, labor & human rights, ethics, and sustainable procurement impacts. NorthX has been rated on the material issues that are relevant to our company’s size, location, and industry.
It is important as a company to manage sustainability risks, and the Pharma industry is no exception. Our goal is to provide sustainable process development and manufacturing services at our company.
If we look closer at the environmental area, we have improved our preventive work such as decreasing our impact on the environment and the municipality’s treatment plant. We now know more about the characteristics of our wastewater and how to handle our hazardous waste which gives us a better chance to improve and become more sustainable.
In the ethics area, we also have improved our preventative work such as implementing policies on information security, ethics issues and corruption. It is important to us that we also have a sustainable production and use raw materials that have been ethically made.
It is also important for us to have good work health and equality. At NorthX we have good diversity, equity, and inclusion of all employees. It is important that our employees stay safe and healthy for a sustainable workplace. We do preventive workthrough risk assessment, information sharing, and education.
We thank all of our employees for the work they have done for this rating and look forward to continuing our improvements in these areas in order to progress in the survey.
Conference “Advanced Biologics in Matfors and Beyond” at NorthX Bio went to a big success!
During a two day conference, a number of key stakeholders from the Swedish and Danish ecosystem visited the Matfors site of NorthX Biologics. The highlight of the tour being the walk about in our GMP licenced facility for ATMP manufacturing as well as the brand new innovation area, delegates also valued the discussions as such. How important it is not least for the government to know we have such capacity on Swedish territory. Yet, from a business perspective of NorthX, the importance to reach beyond the Nordics to showcase how biotechs can use this capacity.
As the conference was such a success, with a waiting list for those that we could not fit, we are already planning for a follow up! Stay tuned.
Photo: the panel visiting the new facility at Matfors.
Xintela and NorthX Biologics announce that they have signed a collaborative framework agreement to jointly accelerate the development of advanced therapeutics (ATMP) by leveraging the companies’ complementary skills and resources in ATMP development and GMP manufacturing. Projects to be initiated within the framework of the collaboration include, among other things, product and process development, quality control and increased expansion capacity for manufacturing ATMPs.
“This is a very interesting opportunity for us. Xintela has developed the unique stem cell product XSTEM, which is now in clinical development, and has strong expertise in process development and GMP manufacturing of stem cells and other ATMPs. Together with NorthX Biologics and their manufacturing capacity, we can further expand and also broaden our ATMP business”, says Evy Lundgren-Åkerlund, CEO of Xintela. “This collaboration is another step in the right direction towards becoming a leading solution provider in the cell and gene therapy space, adding to the solid expertise NorthX has already gained from +30 years of advanced biological GMP manufacturing. I am happy to work with Xintela and look forward to our relationship going forward,” says Helena Strigård, CEO of NorthX Biologics.
Xintela and NorthX Biologics sign framework agreement for collaboration
The Board of NorthX Biologics (“NorthX”) has appointed Helena Strigård as the new CEO. She joins NorthX from her role as Director General for the Swedish life science industry organization, SwedenBIO. Helena will lead NorthX’s continued expansion in the development and production of advanced biologics. Ted Fjällman, current CEO of NorthX and Partner of the Company’s main investor, Flerie Invest, will continue to support the company as a member of the Board.
NorthX has one of Northern Europe’s largest manufacturing capacities for clinical material in the forms of plasmid DNA, recombinant proteins, cell banking, and related gene therapy services. Since the takeover in October 2021, NorthX has recruited a Leadership Team, Sales Team and Board for the rapidly growing company. In addition to the GMP-certified production facility in Matfors, the Company is now establishing itself on the Karolinska University Hospital’s campus in Stockholm and is developing an innovation hub for ATMPs and advanced therapeutics in collaboration with Vinnova, the Swedish Innovation Agency.
NorthX is establishing itself as a partner of choice in the Nordics for cell and gene therapy companies that need GMP manufacturing services. Now the company wants to shift gears to become a global player with a continued strong focus on individual projects and customers, in a spirit of partnership according to the motto “Journey together”. During the first year, Ted Fjällman has had the role of interim CEO and during this time has successfully transitioned NorthX into a Company with all the necessary functions to develop internationally. With that foundation, the Company has now appointed a new CEO, Helena Strigård to continue the Company’s growth. Helena has broad experience from the Ministry of Finance and Vinnova and has taken the organization SwedenBIO through a period of rapid expansion, which saw the membership income doubled.
“NorthX has in a short time built up a broad capacity for advanced biologics. I am excited to be joining at this stage in the Company’s growth and will use all my industry know-how and global network to ensure that we succeed,” said Helena Strigård.
“Under Helena’s leadership, SwedenBIO has taken its place on international arenas to the benefit of the entire industry. NorthX will be able to leverage that driving force to achieve international impact. As a Board we look forward to working with her in order to achieve this important goal. I would like to take this opportunity to thank Ted Fjällman for his successful efforts as interim CEO; he has laid an important foundation for continued success for NorthX and I am grateful that he continues to serve on the Company’s Board”, added Thomas Eldered, chairman of the board of NorthX.
What: Seminar Where: Klara Strand, Klarabergsviadukten 90, Stockholm When: 19th October
We are organizing a seminar on “Drug development of Today and the Future” in collaboration with Abera Biosciences AB, Testa Center, RISE Research Institutes of Sweden, STUNS Life science and Business Sweden on the 19th of October 2022.
We are using this opportunity to invite you to participate to this event.
Be present to hear our own Eva-karin Gidlund and other eminent speakers engaged in the development of drugs talking about opportunities, problems and practical examples of the field where innovative ways of collaboration and new acquired skills were essential to surmount hurdles associated with our branch’s new demands.
The future is coming in fast, with it new challenges arise for all of us who are active in our industry. This seminar is intendent to be a platform for networking, exchange of ideas, best practices and possible solutions.
We eagerly await your participation in the seminar!
Preliminary program:
15:00 – Introduction 15:05 – Jesper Hedberg (Testa Center) 15:15 – Matti Sällberg (pre – GMP facillity) 15:25 – Eva-karin Gidlund (NorthX Biologics) 15:35 – Anna Ridderstad Wollberg (RISE) 15:45 – Coffee break 16:00 – Maria Alriksson (Abera Biosciences) 16:15 – Angelica Loskog (Lokon Pharma) 16:30 – Charlotte af Klercker & Britta Stenson (Business Sweden, followed by Q&A and discussions) 17:00 -19:00 – Mingle with snacks
Today we can announce that we are expanding within the production of cell therapy, i.a. via partnership with Alder Therapeutics and that we are expanding with a second manufacturing facility at Karolinska.
“We welcome Dave Smith from Akron Bio and Ola Tuvesson from NorthX Biologics to present and discuss the critical functions of CMOs and their role in managing the challenges of adapting from traditional biologics to ATMPs.”
